Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

Also known as: Metastatic Colorectal Cancer / Colorectal Cancer Metastatic / Cancer - Metastatic Colorectal / Metastatic Colorectal Cancer (MCRC) / Colorectal Cancer, Metastatic / Secondary malignant neoplasm of colon and/or rectum (disorder) / Secondary malignant neoplasm of large intestine (disorder)

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04430985FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal CancerTreatment
NCT04513951AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer PatientsTreatment
NCT04034459FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCTreatment
NCT04097444CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRCTreatment
NCT01531595Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal CancerTreatment
NCT01991873Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerTreatment
NCT02980510Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer PatientsTreatment
NCT03117972Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 LevelsTreatment
NCT04245865Tocotrienol and Bevacizumab in Metastatic Colorectal CancerTreatment
NCT03388190METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinTreatment
NCT03792269Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRCTreatment
NCT04169347FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerTreatment
NCT03164655Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy NetworkTreatment